2 weeks post partum her FEV, was 25% (FEVI/FVC 800/1250mL) with PaO2 9.43 kPa and PaCO2 8.58 kPa on 28% FiO2. Her weight rose from 39.5 kg immediately after delivery to 46.5 kg 9 weeks post partum. She remained in hospital for about 4 months for treatment of further infective exacerbations. As her blood gases deteriorated she required an increase to 35% FiO2 and nocturnal BiPAP. She was discharged with FEV1 18% and PaO2 9.10 kPa, PaCO2 7.49 kPa and pH 7.43 on 35% FiO2. However, she was soon readmitted with a further exacerbation and worsening respiratory failure. She died 7 months post partum. COMMENT NIPPV is an established treatment for hypercapnic respiratory failure3. It allows correction of hypoxaemia by increasing the FiO2 without an unacceptable rise in PaCO2. It has been used in cystic fibrosis4 and in a pregnant patient with primary hypoventilation5, but previous reviews do not mention its use in pregnant patients with cystic fibrosisl ,2,4. In our patient it produced clinical improvement and contributed to achievement of an acceptable length of gestation.
Pneumothorax is a potential hazard of NIPPV, but it is also a common complication of cystic fibrosis where the risk is related to the severity of the lung disease. This patient was therefore already at high risk of pneumothorax. Surgical or thoracoscopic repair should be considered early for a persistent pneumothorax6. However, as in our patient, surgery may not be feasible in the presence of severe underlying lung disease. This patient's pneumothorax finally resolved with conventional treatment; furthermore NIPPV was used later without recurrence. (Figure 1) . Her general condition improved on oral co-amoxiclav and ciprofloxacin and she was discharged after 6 weeks. 4 weeks later she was readmitted with similar symptoms, a right hypoglossal nerve palsy and conductive deafness. ESR was 76 mm, CRP 71 mg/L. Computed tomography of the skull showed right mastoid opacification, and surgical exploration revealed abnormal bone. A working diagnosis of osteomyelitis was confirmed by a technetium methylene diphosphonate bone scan, which showed increased uptake in the right petrous temporal bone. Because of the risk of ototoxicity with gentamicin, an allergic reaction to ceftazidime, and diarrhoea with clindamycin she was treated for 6 weeks with intravenous imipenem. Symptoms and biochemical inflammatory indices resolved and bone uptake on Tc-99 white-cell scans declined.
2 weeks after stopping antibiotics she presented again with right facial pain and her ESR was high. Nasal biopsies grew two pseudomonal species; granulomatous disease was absent. After a further 2 months of imipenem and four months of high-dose oral ciprofloxacin, serial whitecell scans and biochemical indices confirmed clinical resolution. COMMENT Pseudomonal osteomyelitis of the skull base, described by Meltzer and Keleman in 19591, can result from malignant external otitis2 an invasive bacterial (invariably Pseudomonas aeruginosa) infection of the external auditory meatus to which diabetics and immunocompromised patients are prone. The features include unilateral unremitting headache, conductive hearing loss, progressive cranial neuropathies, venous sinus thrombosis, intracerebral abscesses, meningitis and internal carotid artery infiltration3. Chronic pseudomonal sinusitis, unlike malignant external otitis, has seldom been reported as progressing to skull base osteomyelitis. In our patient, diabetic microangiopathy in the paranasal sinuses could have facilitated the spread of infection to the petrous temporal bone.
Although Tc-99 bone scans detect bone involvement earlier than computed tomography44, and gallium-67-citrate bone scans have been used for monitoring disease resolution6, our experience suggests that serial Tc-99 white-cell scans in combination with either computed tomography or MRI5 are the best imaging techniques for diagnosis and monitoring in this disease. For treatment a combination of two antipseudomonal agents is generally recommended until there is clinical, biochemical, and radionuclide improvement; long and repeated courses may be required2. However, high-dose oral ciprofloxacin alone for up to 15 weeks has maintained disease remission6.
